Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy
21
TL;DR: In this paper , an engineered MDA-MB-231 cell line was used for harvesting extracellular vesicles (EVs), which can be used for cancer concurrent immunotherapy and chemotherapy.
read more
About: This article is published in Bioactive Materials. The article was published on 01 Mar 2022. and is currently open access. The article focuses on the topics: Cytotoxicity & Cancer research.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Engineered exosomes from different sources for cancer-targeted therapy
Menghui Zhang,Shengyun Hu,Lin Liu,Pengyuan Dang,Yang Liu,Zhenqiang Sun,Bingbing Qiao,Chengzeng Wang +7 more
TL;DR: In this paper , the authors summarized the characteristics of engineered exosomes, especially the spatial and temporal properties, and concluded that the recent advances in the cancer fields, including the sources, isolation technologies, modification strategies, and labeling and imaging methods, can be summarized, such as photodynamic therapy, gene therapy, and immunotherapy.
Engineered extracellular vesicles and their mimetics for cancer immunotherapy.
Chun-Ping Liu,Yichao Wang,Longmei Li,Dongyue He,Jiaxin Chi,Qin Li,Yixiao Wu,Yunxuan Zhao,Shihui Zhang,Lei Wang,Zhijin Fan,Yuhui Liao +11 more
TL;DR: Extracellular Vesicles (EVs) are heterogeneous membranous vesicles secreted by living cells that are involved in many physiological and pathological processes as intermediaries for intercellular communication and molecular transfer as mentioned in this paper .
92
Cell-derived nanovesicles prepared by membrane extrusion are good substitutes for natural extracellular vesicles
TL;DR: In this paper , the similarity of membrane proteins between the two groups was found to be ∼71%, while it was only ∼21% when pertaining to total protein cargo. But no significant difference was found in size, morphology, and classical markers between nEVs and CNVs derived from MDA-MB-231 cells.
56
Advances in Extracellular Vesicle Nanotechnology for Precision Theranostics
Qian Wu,Siyuan Fu,Hanyang Xiao,Jiaxin Du,Fang Cheng,Shuangshuang Wan,Houjuan Zhu,Dan Li,Fei Peng,Xianguang Ding,Lianhui Wang +10 more
TL;DR: Extracellular vesicles (EVs) have increasingly been recognized as important cell surrogates influencing many pathophysiological processes, including cellular homeostasis, cancer progression, neurologic disease, and infectious disease as discussed by the authors .
48
Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies
Jiaxing Liu,Xueqiang Peng,Shuo Yang,Xinyu Li,Ming-Lih Huang,Shibo Wei,Sheng Zhang,Guangpeng He,Hongyu Zheng,Qing Fan,Liang Wang,Han Li +11 more
TL;DR: In this paper , the authors explore the production, regulation and tumor immunosuppression of PD-L1 on the surface of tumor cells and extracellular vesicles, as well as the potential clinical application of extraneous vesicle PD-l1 as tumor biomarkers and therapeutic targets.
References
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf,Florin-Andrei Taran,Markus Wallwiener,Christina B. Walter,Bernhard K. Krämer,Eva-Maria Grischke,Sara Y. Brucker +6 more
TL;DR: This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
Exosomes: composition, biogenesis and function
TL;DR: The physical properties that define exosomes as a specific population of secreted vesicles are described, their biological effects, particularly on the immune system, are summarized, and the potential roles that secretedvesicles could have as intercellular messengers are discussed.
5.2K
Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS.
TL;DR: Practical, experimental approaches for studying, identifying, and eliminating the effect of matrix on the results of quantitative analyses by HPLC-MS/MS are described and it is demonstrated that, for the investigational drug under study, the matrix effect was clearly observed when ISP interface was utilized but it was absent when the HN interface was employed.
5.1K
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst,Jean-Charles Soria,Marcin Kowanetz,Gregg Fine,Omid Hamid,Michael S. Gordon,J. A. Sosman,David F. McDermott,John D. Powderly,Scott N. Gettinger,Holbrook E Kohrt,Leora Horn,Donald P. Lawrence,Sandra Rost,Maya Leabman,Yuanyuan Xiao,Ahmad Mokatrin,Hartmut Koeppen,Priti S. Hegde,Ira Mellman,Daniel S. Chen,F. Stephen Hodi +21 more
TL;DR: Evaluated data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment, as well as across multiple cancer types.
5K
Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response
Chen Gang,Alexander C. Huang,Wei Zhang,Wei Zhang,Gao Zhang,Wu Min,Wei Xu,Zi-Li Yu,Jiegang Yang,Jiegang Yang,Beike Wang,Beike Wang,Honghong Sun,Hou-Fu Xia,Qiwen Man,Wenqun Zhong,Wenqun Zhong,Leonardo F. Antelo,Bin Wu,Xuepeng Xiong,Xiaoming Liu,Lei Guan,Lei Guan,Ting Li,Ting Li,Shujing Liu,Ruifeng Yang,Youtao Lu,Liyun Dong,Suzanne McGettigan,Rajasekharan Somasundaram,Ravi Radhakrishnan,Gordon B. Mills,Yiling Lu,Junhyong Kim,Youhai H. Chen,Haidong Dong,Yi-Fang Zhao,Giorgos C. Karakousis,Tara C. Mitchell,Lynn M. Schuchter,Meenhard Herlyn,E. John Wherry,Xiaowei Xu,Wei Guo +44 more
TL;DR: It is reported that metastatic melanomas release extracellular vesicles, mostly in the form of exosomes, that carry PD-L1 on their surface, suggesting a mechanism by which tumours could evade the immunesystem, and the potential application ofExosomal PD- L1 to monitor patient responses to checkpoint therapies.